Advertisement

Molecular Imaging and Biology

, Volume 7, Issue 3, pp 197–200 | Cite as

How Available is Positron Emission Tomography in the United States?

  • James C. PattersonIIEmail author
  • Michael L. Mosley
Editorial/Commentary

Abstract

Purpose

Positron emission tomography (PET) has become a major clinical diagnostic and prognostic tool for oncology and multiple other arenas. To some, however, the perception exists that PET is not available as a resource in their community. Our goal with this project was to determine how available clinical PET was in the United States.

Procedures

We used existing lists of PET centers, websites from PET scanner manufacturers, as well as a common Internet search engine to find clinical PET facilities. A mapping program was then used to determine area coverage with a 75-mile radius for each PET scanner found, and the United States Census website was utilized as a source of population data for covered and not covered areas.

Results

We found that 97% of the US population lives within 75 miles of a clinical PET facility.

Conclusion

Thus, it appears that the idea of clinical PET being unavailable to many is a misconception, which may be limiting its use by some physicians who are unaware of how common it has become.

Key words

PET availability United States Center for Medicare and Medicaid Services Reimbursement Mobile PET 

References

  1. 1.
    Patterson, J, Lilien, D, Tainter, K,  et al. 2004FDG PET detection of mild cognitive impairment with the cognitive decline indexBiol Psychiatry5554SAbstractGoogle Scholar
  2. 2.
    Department of Health and Human Services (DHHS) (2001). Expanded coverage of positron emission tomography (PET) scans and related claims processing changes. Health Care Financing Administration Publication 60AB. Transmittal AB-01-54. April 10Google Scholar
  3. 3.
    Center for Medicare and Medicaid Services (CMS) (2004). Decision memo for positron emission tomography (FDG) and other neuroimaging devices for suspected dementia. CAG-00088R. Sept 15Google Scholar
  4. 4.
    Leon, MJ, Convit, A, Wolf, OT,  et al. 2001Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET)Proc Natl Acad Sci U S A981096610971CrossRefPubMedGoogle Scholar
  5. 5.
    Reiman, EM, Caselli, RJ, Chen, K,  et al. 2001Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s diseaseProc Natl Acad Sci U S A9833343339CrossRefPubMedGoogle Scholar
  6. 6.
    Small, GW, Ercoli, LM, Silverman, DH,  et al. 2000Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s diseaseProc Natl Acad Sci U S A9760376042CrossRefPubMedGoogle Scholar
  7. 7.
    Santi, S, Leon, MJ, Rusinek, H,  et al. 2001Hippocampal formation glucose metabolism and volume losses in MCI and ADNeurobiol Aging22529539PubMedGoogle Scholar
  8. 8.
    RFA-AG-04-005. The Alzheimer’s Disease Neuroimaging Initiative. http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-04-005.html

Copyright information

© Academy of Molecular Imaging 2005

Authors and Affiliations

  1. 1.Biomedical Research Foundation of Northwest LouisianaLouisiana State University Health Science CenterShreveportUSA

Personalised recommendations